Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2002

View Archived Issues

Cell therapy as a treatment for myocardial infarction and heart failure

Endo updates investors at healthcare conference

Squalamine enters clinical trials for fibrodysplasia ossificans progressiva

Generex's buccal morphine demonstrates proof of concept in phase I study

AtheroGenics aggressively developing lead compound

ProSorb formulation of pain medication enters pivotal trials

Activity and adequate safety demonstrated in phase II trial of Onconase in malignant mesothelioma

Orally and topically administered C5a antagonist effective in dermal immunoinflammatory reaction

Potent and selective ETA receptor antagonist potently lowers blood pressure in rats

Efficacy of novel mucosal vaccine delivery system described by RxKinetix in recent article

Corixa and Beaufour Ipsen collaborate on AnergiX.MG technology for myasthenia gravis

Oxford GlycoSciences, Medarex and Genmab in new initiative against cancer

Enbrel approved for treatment of psoriatic arthritis

Phase 2 Discovery to develop LY-156735 for sleep disorders

Risedronate receives approval in Japan

Alizyme's mucositis drug ATL-104 proves safe and well tolerated in phase Ia trial

Board recommends continuing phase III trial of Actimmune for IPF

Alliance looks to resume phase III program for Oxygent

Palonosetron completes phase III trials for CINV

New NK1 receptor antagonists described recently by Roche

Preparation and use of new thiourea NPY Y1 antagonists for eating disorders

Anticoagulants derived from phenylglycine at Roche

European scientists design triterpenoids which inhibit CDKs

MMP inhibitors and potential uses thereof reported by Aventis

Vertex researchers synthesize series of caspase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...